Charles Schwab Investment Management Inc Rhythm Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $527 Billion
  • Q4 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 440,250 shares of RYTM stock, worth $23.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
440,250
Previous 433,866 1.47%
Holding current value
$23.4 Million
Previous $22.7 Million 8.27%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 06, 2025
BUY
$46.91 - $67.33 $299,473 - $429,834
6,384 Added 1.47%
440,250 $24.6 Million
Q3 2024

Nov 12, 2024
BUY
$40.81 - $55.0 $241,105 - $324,940
5,908 Added 1.38%
433,866 $22.7 Million
Q2 2024

Aug 12, 2024
BUY
$35.41 - $44.37 $751,152 - $941,220
21,213 Added 5.22%
427,958 $17.6 Million
Q1 2024

May 08, 2024
BUY
$39.12 - $52.44 $354,427 - $475,106
9,060 Added 2.28%
406,745 $17.6 Million
Q4 2023

Feb 06, 2024
BUY
$21.39 - $49.64 $276,722 - $642,192
12,937 Added 3.36%
397,685 $18.3 Million
Q3 2023

Nov 08, 2023
BUY
$15.81 - $27.8 $540,528 - $950,454
34,189 Added 9.75%
384,748 $8.82 Million
Q2 2023

Aug 09, 2023
BUY
$16.32 - $21.15 $2 Million - $2.59 Million
122,522 Added 53.73%
350,559 $5.78 Million
Q1 2023

May 11, 2023
SELL
$16.88 - $34.24 $31,717 - $64,336
-1,879 Reduced 0.82%
228,037 $4.07 Million
Q4 2022

Feb 13, 2023
BUY
$22.21 - $30.25 $569,619 - $775,821
25,647 Added 12.56%
229,916 $6.7 Million
Q3 2022

Nov 14, 2022
BUY
$4.3 - $30.85 $135,617 - $972,978
31,539 Added 18.26%
204,269 $5.01 Million
Q2 2022

Aug 15, 2022
SELL
$3.12 - $12.25 $391,856 - $1.54 Million
-125,595 Reduced 42.1%
172,730 $717,000
Q1 2022

May 13, 2022
BUY
$6.13 - $12.24 $56,512 - $112,840
9,219 Added 3.19%
298,325 $3.44 Million
Q4 2021

Feb 11, 2022
BUY
$8.62 - $13.9 $196,053 - $316,141
22,744 Added 8.54%
289,106 $2.89 Million
Q3 2021

Nov 16, 2021
SELL
$11.68 - $20.72 $14,821 - $26,293
-1,269 Reduced 0.47%
266,362 $3.48 Million
Q2 2021

Aug 16, 2021
BUY
$18.52 - $22.55 $285,374 - $347,472
15,409 Added 6.11%
267,631 $5.24 Million
Q1 2021

May 17, 2021
BUY
$20.25 - $39.49 $877,817 - $1.71 Million
43,349 Added 20.75%
252,222 $5.37 Million
Q4 2020

Feb 16, 2021
BUY
$21.17 - $32.61 $66,304 - $102,134
3,132 Added 1.52%
208,873 $6.21 Million
Q3 2020

Nov 13, 2020
SELL
$18.13 - $30.61 $79,463 - $134,163
-4,383 Reduced 2.09%
205,741 $4.46 Million
Q2 2020

Aug 14, 2020
BUY
$14.41 - $25.35 $327,150 - $575,521
22,703 Added 12.11%
210,124 $4.69 Million
Q1 2020

May 15, 2020
BUY
$13.16 - $22.9 $51,442 - $89,516
3,909 Added 2.13%
187,421 $2.85 Million
Q4 2019

Feb 07, 2020
BUY
$19.53 - $25.5 $1.02 Million - $1.33 Million
52,296 Added 39.85%
183,512 $4.21 Million
Q3 2019

Nov 08, 2019
BUY
$18.62 - $24.51 $53,569 - $70,515
2,877 Added 2.24%
131,216 $2.83 Million
Q2 2019

Aug 09, 2019
BUY
$21.11 - $28.48 $399,337 - $538,756
18,917 Added 17.29%
128,339 $2.82 Million
Q1 2019

May 14, 2019
BUY
$24.76 - $31.66 $121,324 - $155,134
4,900 Added 4.69%
109,422 $3 Million
Q4 2018

Feb 14, 2019
SELL
$24.11 - $31.34 $30,643 - $39,833
-1,271 Reduced 1.2%
104,522 $2.81 Million
Q3 2018

Nov 13, 2018
BUY
$26.99 - $35.85 $1.57 Million - $2.09 Million
58,198 Added 122.28%
105,793 $3.09 Million
Q2 2018

Aug 08, 2018
BUY
$17.02 - $35.2 $267,128 - $552,464
15,695 Added 49.2%
47,595 $1.49 Million
Q1 2018

May 07, 2018
BUY
$19.9 - $32.25 $16,298 - $26,412
819 Added 2.64%
31,900 $635,000
Q4 2017

Jan 17, 2018
BUY
$22.0 - $30.51 $683,782 - $948,281
31,081
31,081 $904,000

About RHYTHM PHARMACEUTICALS, INC.

RYTM Quotes by TradingView
  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.97B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email